Skip to content
naulon

Not checkedNot checked for notices yet.

48 Usability testing of a musculoskeletal digital assessment routing tool: an iterative convergent mixed methods study

Dylan Morrissey, William Marsh, Cabella Lowe and 1 more

BMJ Open Sport & Exercise Medicine · 2022

doi:10.1136/bmjsem-2022-sportskongres.11 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Introduction Digital technologies improving clinical outcomes and efficiency are prioritized for development. We have developed a musculoskeletal Digital Assessment Routing Tool (DART) directing users to right care, first time. DART requires usability testing prior to clinical trials. Materials and Methods An iterative-convergent mixed-methods design was used to assess and mitigate DART usability issues. 22 participants used 50 musculoskeletal presentations across 4 DART iterations during 5 testing rounds. Recruitment quotas for age, habitual internet use and English language ability were used. Constructs of the ISO 9241-210-2019 standard defined quantitative data collection, with user satisfaction measured by the system usability scale. Study endpoints were mitigation of significant usability problems and a mean satisfaction score of 80+ across a minimum of 3 testing rounds. Results All test assessments gave a recommendation with no system errors. Usability problems reduced from 12 to zero. Mean assessment time was 5 minutes (range 1–18), 6 minutes for non-native English speakers. Differences in satisfaction scores were present between groups, expert internet users having the highest mean score (86.5, SD 4.48, CI 90% 1.78), compared with non-native English speakers (78.1, SD 4.60, CI 90% 9.17) and less experienced internet users scoring the lowest (70.8, SD 5.44, CI 90% 3.79). The mean score across all groups was 84.3 (84.3, SD 12.73, CI 90% 4.67), with qualitative data from all participants confirming DART was simple to use. Conclusion With all significant usability problems addressed DART can proceed to a randomized controlled trial assessing safety and effectiveness against a usual care comparator.

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.